Samir Habashi, MD
Gastroenterology · Gainesville, FLNPI 1043379738
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 49.6% of the total. Reporting peaked in 2021 at $1,123 and has fallen 59.2% since, to $458 in 2024. That places this record below the midpoint for gastroenterology clinicians in FL, where the typical reported total is $3,025.
Across 225 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$425
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$289
- Pfizer$211
- Madrigal Pharmaceuticals$133
- E.r. Squibb & Sons, L.L.C.$127
- plus $599 from 12 others
Across 19 payments — averaging $11,115 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$118K
- AbbVie$33K
- Sanofi US Services Inc.$27K
- E.r. Squibb & Sons, L.L.C.$18K
- Janssen Research & Development, LLC$12K
- Phathom Pharmaceuticals, Inc.$3K
What the payments were for
- Food & beverage$3,531100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 128 | $1,756 |
| Gilead | 30 | $425 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $289 |
| Pfizer | 9 | $211 |
| Madrigal Pharmaceuticals | 1 | $133 |
| E.r. Squibb & Sons, L.L.C. | 2 | $127 |
| Janssen Scientific Affairs, LLC | 1 | $105 |
| Vivus LLC | 7 | $90 |
| Johnson & Johnson | 9 | $89 |
| Bristol Myers Squibb | 5 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| Redhill Biopharma Inc. | 3 | $43 |
| Ironwood Pharmaceuticals, Inc | 2 | $32 |
| Intercept Pharmaceuticals, Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Merck | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,540 in reported general payments places this provider in the 50th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 11 | $329,454 |
| XifaxanRifaximin | 25 | $85,930 |
| CreonLipase/Protease/Amylase | 18 | $33,410 |
| LinzessLinaclotide | 22 | $12,683 |
| Lubiprostone | 47 | $7,970 |
| Omeprazole | 399 | $5,552 |
| Esomeprazole Magnesium | 93 | $5,158 |
| Ondansetron OdtOndansetron | 37 | $1,709 |
| CholestyramineCholestyramine (With Sugar) | 14 | $1,629 |
| Dicyclomine Hcl | 60 | $1,474 |
| Pantoprazole Sodium | 132 | $1,262 |
| Sucralfate | 51 | $1,131 |
| Famotidine | 64 | $889 |
| Clarithromycin | 30 | $731 |
| Promethazine Hcl | 20 | $464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $89 | $329,45411 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $289 | $85,93025 claims |
| AbbVieCreon, Linzess | $1,756 | $46,09340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Gainesville
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Arin NewmanMiami Beach$716K
- Joanna LopezMiami$670K
- Jose NietoSebring$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.